Streetbeat News

Revenues

RZLT

Rezolute, Inc. announced positive results from a preclinical pharmacology study validating the potential of its lead clinical compound, RZ358, for treating individuals with non-islet cell tumors that have uncontrolled hypoglycemia. This development marks a significant step forward in addressing a critical unmet medical need.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:38 pm

ANF

Abercrombie & Fitch (ANF) projects its Q1 fiscal 2024 revenue to increase by low double digits year-over-year from $836 million, surpassing the $987.05 million estimate. The company anticipates an operating margin between 8% to 10%, up from 4.6% in Q1 2023, and an effective tax rate of about 10%, lower than its statutory rate due to expected discrete federal income tax benefits from share-based compensation vesting.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:36 pm

BWAY

BrainsWay has projected its full-year 2024 revenue to be between $37M and $40M, surpassing the estimated $35.7M. The company also expects to maintain its profitability momentum and continue generating cash.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:35 pm

ANF

Abercrombie & Fitch projects FY24 revenue to be between $4.47B and $4.56B, surpassing the $4.26B estimate. The company anticipates 4% to 6% sales growth from $4.3B in FY23, despite a $50M impact from an extra reporting week. Abercrombie brands are expected to outperform Hollister, with stronger growth in the Americas and the first half of the year. Operating margin is forecasted at 12%, up from 11.4%, with capital expenditures at $170M. The effective tax rate is expected to be mid-to-high 20s.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:34 pm

BWAY

BrainsWay (NASDAQ:BWAY) reported Q4 sales of $9.03M, surpassing the $8.42M estimate by 7.23% and marking a 49.66% increase from the previous year's $6.03M.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:32 pm

XERS

Xeris Biopharma projects its 2024 revenue to be between $170M-$200M, aligning with the consensus estimate of $184.11M. The company also forecasts year-end cash, cash equivalents, and short-term investments to range from $55M to $75M.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:08 pm

KMDA

Kamada Ltd. projects its 2024 revenues to be between $156M-$160M, below the consensus estimate of $166.14M, with adjusted EBITDA expected to be $27M-$30M. The company anticipates double-digit growth in both top- and bottom-line figures and is exploring new business development opportunities to further enhance future growth.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:07 pm

REVG

REV Group has updated its fiscal year 2024 outlook, expecting net sales to range between $2.45B and $2.55B, down from the prior guidance of $2.60B to $2.70B. This revision places the forecast below the estimated $2.61B. Additionally, adjustments were made to net income, adjusted EBITDA, adjusted net income, and adjusted free cash flow projections.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:04 pm

XERS

Xeris Biopharma Holdings (NASDAQ:XERS) reported Q4 GAAP EPS of $(0.10), meeting analyst consensus estimates, with sales of $44.39M surpassing the $43.55M estimate, marking a 33.93% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:04 pm

KMDA

Kamada (NASDAQ:KMDA) reported Q4 earnings of $0.09 per share, surpassing the $0.05 estimate, marking an 80% beat and a 28.57% increase from last year. However, their Q4 sales of $36.43M fell short of the $37.71M estimate, a 3.39% miss and a 19.82% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 12:03 pm